CYP3A5 and chronic myelogenous leukemia, BCR-ABL1 positive: CYP3A5*3 and ABCB1 C3435T variants influence clinical outcomes and plasma concentrations of Imatinib in Nigerian patients with chronic myeloid leukaemia.